• Earlier in June 2026, Ionis Pharmaceuticals reported positive longer-term data from its CORE-OLE extension study of olezarsen in severe hypertriglyceridemia, showing mean liver fat returning toward baseline, sustained safety, and over 90% of eligible patients remaining on treatment.
• The combination of durable hepatic effects on MRI, high patient retention, and an 80 mg dosing focus adds weight to olezarsen’s potential role in managing this high-need population.
• We’ll now examine how olezarsen’s longer-term hepatic data and strong patient retention may influence Ionis Pharmaceuticals’ existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Ionis Pharmaceuticals Investment Narrative Recap

To own Ionis, you need to believe its antisense platform can convert late stage assets like olezarsen into durable, multi indication franchises despite pricing and regulatory pressures. The new CORE OLE MRI and retention data strengthen the clinical story for olezarsen in severe hypertriglyceridemia but do not materially change the near term catalyst, which remains the upcoming FDA action on the sHTG filing, nor the key risk around pricing and label decisions.

The most relevant recent announcement here is the FDA’s Priority Review of olezarsen for sHTG, with a 30 June 2026 PDUFA date. The fresh extension data feed directly into investor views on the durability, safety, and dose selection that could shape physician uptake if approval comes through, while also reminding investors that any future price reset across FCS and sHTG remains a central risk to the longer term story.

Yet beneath the positive data, investors should be aware that pricing pressure on olezarsen and its impact on margins could...

Ionis Pharmaceuticals’ narrative projects $2.3 billion revenue and $300.8 million earnings by 2029.

Uncover how Ionis Pharmaceuticals' forecasts yield a $100.92 fair value, a 36% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already assumed Ionis could reach about US$2.8 billion in revenue and roughly US$456 million in earnings, so you should treat the new CORE OLE data as a fresh input that might strengthen or challenge those expectations, especially if you worry that future olezarsen pricing across FCS and sHTG could curb the upside they are banking on.

Explore 3 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth 15% less than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.